Rajesh Kumar Soni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rajesh Kumar Soni has a total of 546 co-authors. Here are the top co-authors by number of shared publications:
- Anna Lasorella
Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, USA
30 shared publications - Antonio Iavarone
Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, USA
30 shared publications - Aram Ko
Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea
30 shared publications - Bianca Pollo
Unit of Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
30 shared publications - Brulinda Frangaj
Columbia University Irving Medical Center
30 shared publications - Danika Sommer
Institute for Cancer Genetics, Columbia University Medical Center, New York, New York
30 shared publications
Latest Publications
- Open Access
Disrupting SORL1-retromer endosomal recycling in mice drives the age-dependent neurodegenerative signature of Alzheimer’s disease
MRI studies have mapped the atrophic signature that distinguishes Alzheimer’s disease (AD), isolating regions differentially vulnerable to its age-dependent neurodegenerative process. An endosomal recycling pathway regulated by the interaction of SORL1 with retromer is pathogenically disrupted in AD. Here we test the hypothesis, that the pathway might drive the neurodegenerative process, via multiple yearlong studies in over 140 wildtype and SORL1 deficient mice, modeling SORL1’s causative mutations. MRI studies revealed that SORL1 deficiency induced an age-dependent AD-pattern of atrophy, centered on the trans-entorhinal cortex, and that atrophy was prevented by SORL1 restoration, secondary to overexpressing the retromer protein VPS26b. Postmortem studies validated that the atrophy reflects neuronal loss. Proteomic profiling revealed that the atrophy is associated with reductions in cell death suppressors, one of which was then found deficient in the trans-entorhinal cortex of AD patients. Besides supporting the hypothesis, when taken together with other findings the results suggest that SORL1-retromer disruptions represent a therapeutically-amenable common ‘neurodegeneration pathway’ in AD.
Open AccessDisrupting SORL1-retromer endosomal recycling in mice drives the age-dependent neurodegenerative signature of Alzheimer’s disease
MRI studies have mapped the atrophic signature that distinguishes Alzheimer’s disease (AD), isolating regions differentially vulnerable to its age-dependent neurodegenerative process. An endosomal recycling pathway regulated by the interaction of SORL1 with retromer is pathogenically disrupted in AD. Here we test the hypothesis, that the pathway might drive the neurodegenerative process, via multiple yearlong studies in over 140 wildtype and SORL1 deficient mice, modeling SORL1’s causative mutations. MRI studies revealed that SORL1 deficiency induced an age-dependent AD-pattern of atrophy, centered on the trans-entorhinal cortex, and that atrophy was prevented by SORL1 restoration, secondary to overexpressing the retromer protein VPS26b. Postmortem studies validated that the atrophy reflects neuronal loss. Proteomic profiling revealed that the atrophy is associated with reductions in cell death suppressors, one of which was then found deficient in the trans-entorhinal cortex of AD patients. Besides supporting the hypothesis, when taken together with other findings the results suggest that SORL1-retromer disruptions represent a therapeutically-amenable common ‘neurodegeneration pathway’ in AD.
- 18 May 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (6) , 1368-1382
H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programs
Polycomb repressive complex 2 (PRC2)-mediated histone H3 K27 trimethylation (H3K27me3) recruits canonical PRC1 (cPRC1) to maintain heterochromatin. In early development, Polycomb-regulated genes can display long-range three-dimensional interactions, many of which resolve during lineage differentiation. Here we report that Polycomb-anchored looping is controlled by H3K27me3 spreading and regulates target gene silencing to influence cell fate specification. Using glioma-derived H3 Lys27-to-Met (H3K27M) mutations as tools to restrict H3K27me3 spreading, we show that H3K27me3 confinement concentrates the chromatin pool of cPRC1, resulting in heightened three-dimensional interactions that mirror the chromatin architecture of pluripotency. Conversely, H3K27me3 spread in pluripotent stem cells dilutes local cPRC1 chromatin concentration, weakening Polycomb loop contact frequencies. Disruption of cPRC1 binding or aggregation compromises stringent repression of Polycomb genes and induces differentiation and tumor regression of H3K27M-mutant glioma. These results identify the regulatory principles and disease implications of Polycomb looping and show that histone-modification-guided distribution of reader complexes is an important mechanism for nuclear compartment organization.
- 18 May 2026
- Published by Springer Nature in Nature Genetics
- Vol. 58 (6) , 1368-1382
H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programs
Polycomb repressive complex 2 (PRC2)-mediated histone H3 K27 trimethylation (H3K27me3) recruits canonical PRC1 (cPRC1) to maintain heterochromatin. In early development, Polycomb-regulated genes can display long-range three-dimensional interactions, many of which resolve during lineage differentiation. Here we report that Polycomb-anchored looping is controlled by H3K27me3 spreading and regulates target gene silencing to influence cell fate specification. Using glioma-derived H3 Lys27-to-Met (H3K27M) mutations as tools to restrict H3K27me3 spreading, we show that H3K27me3 confinement concentrates the chromatin pool of cPRC1, resulting in heightened three-dimensional interactions that mirror the chromatin architecture of pluripotency. Conversely, H3K27me3 spread in pluripotent stem cells dilutes local cPRC1 chromatin concentration, weakening Polycomb loop contact frequencies. Disruption of cPRC1 binding or aggregation compromises stringent repression of Polycomb genes and induces differentiation and tumor regression of H3K27M-mutant glioma. These results identify the regulatory principles and disease implications of Polycomb looping and show that histone-modification-guided distribution of reader complexes is an important mechanism for nuclear compartment organization.
- Open Access
- 27 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2559
Comparative Proteomic Analysis of Lipoprotein(a): Method-Dependent Profiles and Disease Pathways
Background: Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD). Proteomic studies suggest that Lp(a)-associated proteins mediate inflammation, thrombosis, and vascular calcification, but methodological variability may influence proteome definition. Methods: Lp(a) was immunoprecipitated from human plasma using an apo(a)-specific monoclonal antibody and analyzed by mass spectrometry following either in-gel digestion or automated in-solution proteolysis. Proteins identified by ≥3 unique peptides and consistently detected across all samples by both methods were considered high confidence. Functional enrichment and interaction networks were assessed using STRING. Results: In-solution proteolysis identified 92 proteins and in-gel digestion identified 55 proteins, with 34 proteins shared between methods. These high-confidence proteins were enriched for pathways involved in lipoprotein remodeling, coagulation regulation, vesicle-mediated transport, lipid binding, and extracellular matrix organization, providing biological insight into mechanisms linking Lp(a) to inflammation, thrombosis, and calcification. Conclusions: Proteome composition of Lp(a) is method-dependent; however, a rigorously defined core proteome of 34 proteins was consistently identified across analytical approaches, highlighting biologically relevant pathways that may underlie Lp(a)-mediated ASCVD risk.
- 27 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (7) , 2559
Open AccessComparative Proteomic Analysis of Lipoprotein(a): Method-Dependent Profiles and Disease Pathways
Background: Lipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD). Proteomic studies suggest that Lp(a)-associated proteins mediate inflammation, thrombosis, and vascular calcification, but methodological variability may influence proteome definition. Methods: Lp(a) was immunoprecipitated from human plasma using an apo(a)-specific monoclonal antibody and analyzed by mass spectrometry following either in-gel digestion or automated in-solution proteolysis. Proteins identified by ≥3 unique peptides and consistently detected across all samples by both methods were considered high confidence. Functional enrichment and interaction networks were assessed using STRING. Results: In-solution proteolysis identified 92 proteins and in-gel digestion identified 55 proteins, with 34 proteins shared between methods. These high-confidence proteins were enriched for pathways involved in lipoprotein remodeling, coagulation regulation, vesicle-mediated transport, lipid binding, and extracellular matrix organization, providing biological insight into mechanisms linking Lp(a) to inflammation, thrombosis, and calcification. Conclusions: Proteome composition of Lp(a) is method-dependent; however, a rigorously defined core proteome of 34 proteins was consistently identified across analytical approaches, highlighting biologically relevant pathways that may underlie Lp(a)-mediated ASCVD risk.
- Open Access
Validation of differentiated sinoatrial-like hiPSCs as a model of native sinus node myocytes
Background: Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) constitute an attractive system for basic research and pharmacologic screening of new molecules of clinical interest. Numerous protocols aiming at differentiating atrial- or ventricular-like cardiomyocytes (hiPSC-CMs) are available. Conversely, only a few are available for obtaining patient-derived sinoatrial node-like pacemaker myocytes (PM-hiPSC-CMs). Here we validate a new protocol to differentiate mature PM-hiPSC-CMs as a model of native sinoatrial node (SAN) myocytes. Methods: We generated PM-hiPSC-CMs through a 2D matrix-sandwich method promoting epithelial-to-mesenchymal transition and small molecule-based temporal modulation of Wnt signaling pathway. In addition, we treated our cells with triiodothyronine, dexamethasone and intracellular cyclic AMP (DTA) to enhance expression of proteins involved in intracellular Ca 2+ handling. Results: Proteomic analyses showed expression of key SAN proteins in DTA-treated PM-hiPSC-CMs. Importantly, expression of proteins related to Ca 2+ handling was increased in DTA-treated PM-hiPSC-CMs compared to untreated ones. DTA-treated PM-hiPSC-CMs displayed action potentials, ionic currents and intracellular Ca 2+ dynamics typical of native SAN. In addition, pacemaker activity responded to both β-adrenergic and muscarinic stimulation. Conclusions: Our data indicate that the differentiation protocol effectively generates PM-hiPSC-CMs with typical native human SAN features. This protocol may serve as a potential approach to generate PM-hiPSC-CMs from patients with history of sinoatrial node disfunction (SND) carrying different mutations in ion channels underlying pacemaking. In addition, these in vitro models of SND could be used for testing long-term vector-based gene therapeutic strategies to handle bradycardia.
Open AccessValidation of differentiated sinoatrial-like hiPSCs as a model of native sinus node myocytes
Background: Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) constitute an attractive system for basic research and pharmacologic screening of new molecules of clinical interest. Numerous protocols aiming at differentiating atrial- or ventricular-like cardiomyocytes (hiPSC-CMs) are available. Conversely, only a few are available for obtaining patient-derived sinoatrial node-like pacemaker myocytes (PM-hiPSC-CMs). Here we validate a new protocol to differentiate mature PM-hiPSC-CMs as a model of native sinoatrial node (SAN) myocytes. Methods: We generated PM-hiPSC-CMs through a 2D matrix-sandwich method promoting epithelial-to-mesenchymal transition and small molecule-based temporal modulation of Wnt signaling pathway. In addition, we treated our cells with triiodothyronine, dexamethasone and intracellular cyclic AMP (DTA) to enhance expression of proteins involved in intracellular Ca 2+ handling. Results: Proteomic analyses showed expression of key SAN proteins in DTA-treated PM-hiPSC-CMs. Importantly, expression of proteins related to Ca 2+ handling was increased in DTA-treated PM-hiPSC-CMs compared to untreated ones. DTA-treated PM-hiPSC-CMs displayed action potentials, ionic currents and intracellular Ca 2+ dynamics typical of native SAN. In addition, pacemaker activity responded to both β-adrenergic and muscarinic stimulation. Conclusions: Our data indicate that the differentiation protocol effectively generates PM-hiPSC-CMs with typical native human SAN features. This protocol may serve as a potential approach to generate PM-hiPSC-CMs from patients with history of sinoatrial node disfunction (SND) carrying different mutations in ion channels underlying pacemaking. In addition, these in vitro models of SND could be used for testing long-term vector-based gene therapeutic strategies to handle bradycardia.
- Open Access
- 6 January 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (1) , 51-66
Pathogenetic mechanisms of muscle-specific ribosomes in dilated cardiomyopathy
The heart uses a muscle-specific ribosome in cardiomyocytes, where the ribosomal protein RPL3 is replaced by its paralog RPL3L. Rare biallelic RPL3L mutations cause fatal neonatal dilated cardiomyopathy, yet the mechanisms that link genotype to heart failure are unclear. Despite the recessive inheritance pattern in humans, Rpl3l knockout mice show no overt cardiac phenotype, probably because of compensatory RPL3 upregulation through unknown mechanisms. Here we report four additional cases and propose a unifying pathogenetic model by integrating human genetics, patient tissues and isogenic cell models. Affected individuals typically carry one of two recurrent hotspot missense variants paired with a private allele. Whereas non-hotspot variants phenocopy knockout and allow RPL3 compensation, hotspot variants induce nucleolar protein aggregation, disrupt rRNA processing and block compensation by preserving the role of RPL3L in repressing RPL3 via unproductive splicing. These findings establish combined loss-of-function and gain-of-function mechanisms for RPL3L-associated cardiomyopathy and inform genetic screening, diagnosis and therapeutic development.
- 6 January 2026
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 5 (1) , 51-66
Open AccessPathogenetic mechanisms of muscle-specific ribosomes in dilated cardiomyopathy
The heart uses a muscle-specific ribosome in cardiomyocytes, where the ribosomal protein RPL3 is replaced by its paralog RPL3L. Rare biallelic RPL3L mutations cause fatal neonatal dilated cardiomyopathy, yet the mechanisms that link genotype to heart failure are unclear. Despite the recessive inheritance pattern in humans, Rpl3l knockout mice show no overt cardiac phenotype, probably because of compensatory RPL3 upregulation through unknown mechanisms. Here we report four additional cases and propose a unifying pathogenetic model by integrating human genetics, patient tissues and isogenic cell models. Affected individuals typically carry one of two recurrent hotspot missense variants paired with a private allele. Whereas non-hotspot variants phenocopy knockout and allow RPL3 compensation, hotspot variants induce nucleolar protein aggregation, disrupt rRNA processing and block compensation by preserving the role of RPL3L in repressing RPL3 via unproductive splicing. These findings establish combined loss-of-function and gain-of-function mechanisms for RPL3L-associated cardiomyopathy and inform genetic screening, diagnosis and therapeutic development.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
The Kelch domain of LZTR1 and carboxyl tail of EGFR are required for their interaction
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
The Kelch domain of LZTR1 and carboxyl tail of EGFR are required for their interaction
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
EGFR and AXL protein expression in the brain and immunohistochemical characterization of tumors of Lztr1fl/fl;Cdkn2afl/fl;GFAP-Cre+ mice
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
EGFR and AXL protein expression in the brain and immunohistochemical characterization of tumors of Lztr1fl/fl;Cdkn2afl/fl;GFAP-Cre+ mice
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
Vulnerability of LZTR1 inactive cells to combination treatment of EGFR and AXL inhibitors
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
Vulnerability of LZTR1 inactive cells to combination treatment of EGFR and AXL inhibitors
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1. from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
LZTR1 regulates EGFR and AXL protein stability
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1. from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
LZTR1 regulates EGFR and AXL protein stability
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
LZTR1 co-localized with EGFR and AXL at the cellular membrane upon ligand stimulation
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL
LZTR1 co-localized with EGFR and AXL at the cellular membrane upon ligand stimulation